Trying to make sense of the clinical trial phases you keep seeing in biotech news? There are four main ones: safety first, then effectiveness, then large confirmation, then monitoring after approval.
| Phase | Typical size and length |
|---|---|
| Phase 1 | 20 to 80 healthy volunteers or people with the condition; several months |
| Phase 2 | A few dozen to about 300 subjects; several months to 2 years |
| Phase 3 | Several hundred to about 3,000 people |
| Phase 4 | Several thousand volunteers who have the condition |
| Phase 1 emphasis | Safety |
| Phase 2 emphasis | Effectiveness |
These figures come from a university research-ethics summary of FDA-style phases, Texas Woman’s University. Ranges vary by disease and drug, so check the source before you rely on them.
This page is part of our wider guide to the biotech industry. It is independent and educational, and it is not connected to any company or agency named here.
Why trials are split into phases
A new treatment cannot go straight from the lab to large numbers of patients. Each phase has a main focus; phases may overlap or be combined, with progression guided by available evidence.
That staged design protects participants. It also lets a developer stop early, before spending large sums on a drug that is unsafe or does not work.
Before testing a new investigational drug in people in the United States, developers generally complete preclinical work and proceed under an IND. A university overview says the IND is a process they must go through before clinical research begins.
If you want the wider picture, the drug development process covers the steps before and after the trials described here.
Phase 1: is it safe?
Phase 1 is usually the first time a treatment is tested in people. The emphasis is on safety: how the body handles the drug and which doses are tolerable.
The summary above says that in most cases 20 to 80 healthy volunteers or people with the condition take part, and the study lasts several months. Some trials combine stages, such as Phase 1/Phase 2 designs.
Because the group is small, investigators watch participants closely and adjust doses carefully. The goal is not to prove benefit but to learn whether it is reasonable to continue and at what dose level.
The result is a first picture of side effects and how the body processes the treatment. That picture decides whether the program earns a place in the next stage.
- Main question: is the treatment safe at the doses tested?
- Who takes part: small groups, sometimes healthy volunteers.
- What counts as a good result: no unacceptable toxicity.
Phase 2: does it seem to work?
Phase 2 begins if Phase 1 does not reveal unacceptable toxicity. While Phase 1 focuses on safety, the emphasis in Phase 2 is on effectiveness.
Participants receiving the drug may be compared with similar participants receiving a placebo or a different drug. The number of subjects typically ranges from a few dozen to about 300, and a study can last from several months to 2 years.
Many drug candidates stop here. A treatment may be safe but show too little benefit to justify a larger trial.
Phase 2 results also shape what comes next. They help the developer choose doses, endpoints and patient groups, so the later, larger trial is designed around real evidence rather than guesses.
For anyone working in the field, this is often where study design skills matter most. A well-chosen question at this stage can save a program from an expensive failure later.
Phase 3: does it hold up in a larger group?
The final pre-approval stage usually follows evidence of effectiveness in the middle stage and often precedes approval; some drugs receive accelerated approval before confirmatory trials are completed. These studies gather more information about safety and effectiveness by studying different populations and different dosages, and by using the drug in combination with other drugs.
Enrolment is much larger than in the earlier stages, so the study can show how the drug performs across many different kinds of participants.
This is the pivotal stage, and its results weigh heavily when a developer prepares a marketing application. Because it is the biggest pre-approval step, it is also usually the costliest and most logistically demanding.
Another university overview notes that a drug developer must include everything from preclinical data to Phase 3 trial data in a new drug application.
Phase 4: what happens after approval?
Phase 4 trials take place after a drug has been cleared for marketing. They are part of post-market safety monitoring.
The same summary says the number of subjects in Phase 4 ranges from several thousand volunteers who have the condition. Larger and longer observation can reveal rare side effects that smaller earlier trials could miss.
Reading trial headlines without being misled
Press releases often announce that a trial “met its goal” without saying how large or how early it was. The phase tells you how much weight to give the result.
Use this short checklist when you read a headline:
- Find the phase. An early result mainly speaks to safety and dosing, not proven benefit.
- Look at the size. A small group can hint at a signal but rarely settles the question.
- Check for a comparison group. Placebo or active-drug comparisons make effectiveness claims more meaningful.
- Note the population. Results in one group may not carry over to another.
- Ask what comes next. A strong result usually just earns the right to the following phase.
None of this replaces reading the full trial report. It simply helps you ask better questions of a headline.
Common misunderstandings
People often assume that a drug in a late phase is almost certain to reach patients. In reality, a late-stage trial can still fail, and the evidence must be reviewed by regulators afterwards.
Another frequent mix-up is treating Phase 1 as a test of whether a drug works. Its emphasis is on safety, so a Phase 1 result tells you little about benefit.
- Phases are not a ranking of how good a drug is, only of how far evidence has progressed.
- Phase 4 does not mean a drug is suspect; it is routine monitoring after marketing.
- Combined designs exist, so a single trial can span two phases.
What the phases mean for a biotech career
Each phase needs different people. Early trials lean on clinical pharmacology and safety expertise, while later ones need large-scale operations, data management, statistics and regulatory writing.
- Early phases: small, intensive studies with close medical oversight.
- Late phases: many sites, many participants, heavy coordination.
- Phase 4: safety monitoring and long-term follow-up.
To see how trials are run day to day, read about what is clinical research. When reading news, note which phase a headline refers to, because a Phase 1 result says much less about benefit than a Phase 3 result.
Frequently asked questions
How many clinical trial phases are there?
Show answer
Four main phases are usually described: Phase 1 to Phase 4. Combined designs such as Phase 1/Phase 2 and Phase 2/Phase 3 also exist.
Which phase is the largest?
Show answer
Later phases usually enrol larger groups than earlier ones, according to the summary cited above.
Do all drugs pass through every phase?
Show answer
No. A treatment moves on only if the evidence supports it, so many stop in Phase 1 or Phase 2.
Are Phase 1 volunteers always healthy?
Show answer
Not always. Participants can be healthy volunteers or people with the disease or condition.
